Last reviewed · How we verify
vaccinate with DTaP
DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens.
DTaP vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens. Used for Prevention of diphtheria in infants and children, Prevention of tetanus in infants and children, Prevention of pertussis (whooping cough) in infants and children.
At a glance
| Generic name | vaccinate with DTaP |
|---|---|
| Sponsor | Zhejiang Provincial Center for Disease Control and Prevention |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
DTaP is a combination vaccine containing inactivated diphtheria and tetanus toxoids and acellular pertussis antigen. Upon administration, these antigens trigger both humoral (antibody) and cell-mediated immune responses, priming the immune system to recognize and neutralize the corresponding pathogens if encountered naturally. This provides protection against diphtheria, tetanus, and pertussis (whooping cough).
Approved indications
- Prevention of diphtheria in infants and children
- Prevention of tetanus in infants and children
- Prevention of pertussis (whooping cough) in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Fussiness or irritability
- Drowsiness
- Loss of appetite
Key clinical trials
- Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea
- Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial (PHASE3)
- Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children (PHASE4)
- Immunogenicity and Safety of DTaP or DT Vaccine in 6 Year Old Children ( DTaP/DT ) (PHASE4)
- Vaccinating Children After Chemotherapy (PHASE4)
- A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers (PHASE2)
- Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age (NA)
- Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: